NATAP is at the 7th Conference on Retroviruses and Opportunistic Infections

NATAP is at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000
Jules Levin, NATAP

* Selected Highlights and Reports from Leading Researchers:

Antiretroviral Therapy Highlights from the 7^th Conference on Retroviruses and Opportunistic Infections by Keith Henry, MD with Editing by Jules Levin;
A special piece written for the NATAP web site by Keith Henry, MD from the HIV Program at Regions Hospital in the University of Minnesota AIDS Clinical Trials Unit, both in St Paul.

Fat Redistribution and Metabolic Disturbances, Graeme Moyle, MD
(The first report of more to come from guest writers for NATAP)

Report 55: COMBINE Study: Nelfinavir+Combivir vs. Nevirapine+Commbivir; Preliminary Results of a Randomized Study Comparing Combivir plus Nevirapine or Nelfinavir in Treatment-NaÔve

Report 54: It Is Safe to Discontinue Secondary Prophylaxis for PCP in HIV-Infected Patients Treated with HAART?

Report 53: Pharmacokinetic Interactions between Protease Inhibitors and 3 Lipid-Lowering Drugs (Pravastatin, Simvastatin, and Atorvastatin)

Report 52: DAPD - preliminary antiviral activity, tolerability, and resistance

Report 51: Report from Retrovirus Conference on Prophylaxis for Opportunistic Infections

Report 50: Lipodystrophy & Women: how long after starting therapy does it take for lipodystrophy to develop; what is the probability of its development?

Report 49: DPC 083: a new NNRTI for resistant virus in early development

Report 48: Selected Perinatal Transmission Studies at Retrovirus

Report 47: Incarceration Plays a Role in Incidence of HIV Among African-Americans: Better Prevention Needed In Prisons

Report 46: Preliminary PMPA Resistance and Antiviral Activity in Treatment Experienced

Report 45: More on Hepatitis C and HIV Co-Infection at Retrovirus

Report 44: Ritonavir Intensification in People Receiving Indinavir with Detectable HIV-RNA

Report 43: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy (after 2 weeks)

Report 42: Double NNRTIs: Nevirapine+Efavirenz; DONUT Study: The Pharmacokinetics (PK) of Once Daily Nevirapine (NVP) and Efavirenz (EFV) When Used in Combination

Report 41: Hydroxyurea+DDI: Control of Viremia after Treatment Interruption; a report from Franco Lori

Report 40: The Relationship between Hepatitis C Virus and HIV Infection in Hemophiliacs

Report 39: Switching Therapy Studies and Responses in Lipodystrophy

Report 38: Sulfa-Associated Rash and Race (Hispanic) are Risk Factors for Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Associated Rash

Report 37: Pegylated Interferon: pharmacokinetics of two Peg-Interferons

Report 36: Nevirapine (VIRAMUNE, NVP) and Ethinyl Estradiol/Norethindrone [ORTHO-NOVUM 1/35 (21 Pack) EE/NET] Interaction Study in HIV-1 Infected-Women

Report 35: Documentation of HIV-1 Superinfection and Acceleration of Disease Progression

Report 34: More on Fat Redistribution and Lipodystrophy: African-Americans, when treated during acute infection, osteopenia, amprenavir

Report 33: New Resistance "Cut-Offs" May Be Needed: Baseline Genotype and Phenotype Do Not Predict Response to ABT-378/Ritonavir in PI-Experienced Patients at 24 and 48 Weeks

Report 32: Potential Clinical Impact of Small Differences between Virco Antivirogram and ViroLogic PhenoSense Assays for Abacavir in 3TC Experienced Patients

Report 31: Decreased HIV-1 Fitness after Long-Term Virologic Failure of Protease Inhibitor-Based Therapy: Relationship to Immunologic Response

Report 30: Potential Importance of Maintaining Full Viral Suppression: Mathematical Model for the Decay of the Replication-Competent Latent Reservoir: Effect of Treatment Interruptions and IL-2 Stimulation

Report 29: HIV-1 Latent Reservoirs Renewed by Viral Replication in Activated CD4+ T Lymphocytes, Monocytes, and Resting CD4+ T Lymphocytes in Patients Receiving Potent Therapy

Report 28: Reduced Susceptibility to NRTI Is Associated with NNRTI Hypersensitivity in Virus from HIV-1-Infected Patients

Report 27: Persistent vRNA in PBMC from HIV-Infected Patients on Potent Antiretroviral Therapy Is Associated with Rare vRNA

Report 26: Ongoing New Infection?: Detection of Circular Viral DNA in PBMC of HIV-Infected Individuals with No Detectable Viral RNA

Report 25: SERUM HCV-RNA, ALT LEVELS AND AST/ALT RATIO DO NOT PREDICT SEVERITY OF LIVER DISEASE IN CHRONIC HEPATITIS C VIRUS INFECTION

Report 24: New Resistance Cut-Offs" May Be Needed:
Baseline Genotype and Phenotype Do Not Predict Response to ABT-378/Ritonavir in PI-Experienced Patients at 24 and 48 Weeks

Report 23: Potential Clinical Impact of Small Differences between Virco Antivirogram and ViroLogic PhenoSense Assays for Abacavir in 3TC Experienced Patients.

Report 22: Selection of Antiretroviral Resistance in the Latent Reservoir of Human Immunodeficiency Virus Type 1 during Successful Therapy

Report 21: Switching to Nevirapine from Protease Inhibitor for Lipodystrophy: preliminary 48-week follow-up

Report 20: Incarceration Plays a Role in Incidence of HIV Among African-Americans: Better Prevention Needed In Prisons

Report 19: T-20 and T-1249: fusion inhibitors

Report 18: HIV & Women

Report 17: Conference Late Breakers: Two Therapy Interruption Studies

Report 16: Primary HIV Infections Associated with Oral Transmission

Report 15: Bone Mineral Density

Report 14: Pharmacokinetics of the Triple Combination of Saquinavir, Ritonavir, and Efavirenz in HIV-Positive Patients

Report 13: Tipranavir: new protease inhibitor for PI resistance

Report 12: Fat Redistribution, Lipodystrophy and Related Issues

Report 11: STIs to Strategic Treatment Interruptions: despite undetectable resistance in plasma after interruption, resistance detected in PBMCs

Report 10: ABT-378/ritonavir in Treatment-Experienced-- 48-Weeks Follow-Up

Report 9: Amprenavir + Ritonavir + Efavirenz: Pharmacokinetics; and, Pharmacokinetic (PK) Drug-Interaction between Amprenavir and Ritonavir in HIV- Individuals

Report 8: Treatment Issues for Preventing Mother To Infant HIV Transmission

Report 7: Post-Exposure Prophylaxis For Sexual and Occupational Exposure

Report 6: Methadone Dosing & Nelfinavir, Nevirapine, & Efavirenz

Report 5: ABT-378/ritonavir in Treatment-NaÔve: 72 Week Update

Report 4: Drug Resistance and Viral Reservoirs
- Viral load blips can result in resistance
- IL-2 does not appear to clear HIV from lymph node
- After viral load rebound, virus from various reservoirs may become activated

Report 3: The Importance of Adherence -- Impact of Directly Observed Therapy on Outcomes in HIV Clinical Trials

Report 2: Phenotypic Drug resistance Testing: VIRA 3001

Report 1: Two studies on Women & HIV reported at today's Retrovirus Conference